Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.8% – Here’s Why

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares traded down 7.8% during mid-day trading on Monday . The stock traded as low as $5.82 and last traded at $5.8750. Approximately 454,068 shares were traded during mid-day trading, an increase of 46% from the average session volume of 311,824 shares. The stock had previously closed at $6.37.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The business’s 50-day moving average is $20.01 and its two-hundred day moving average is $25.09.

Regencell Bioscience (NASDAQ:RGC) last posted its earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new stake in shares of Regencell Bioscience in the 4th quarter worth approximately $92,000. Amundi acquired a new position in Regencell Bioscience in the first quarter worth approximately $219,000. Hudson Bay Capital Management LP bought a new stake in shares of Regencell Bioscience during the 4th quarter worth about $275,000. Bank of America Corp DE lifted its position in Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after acquiring an additional 17,143 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Regencell Bioscience during the third quarter worth $598,000. 0.13% of the stock is currently owned by institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.